Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis (vol 80, pg 789, 2023)

被引：0
|
作者：
不详
机构：
来源：
JAMA NEUROLOGY | 2023年 / 80卷 / 10期
关键词：
D O I：
10.1001/jamaneurol.2023.2958
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1119 / 1119
页数：1
相关论文
共 50 条
  • [1] Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
    Roos, Izanne
    Hughes, Stella
    McDonnell, Gavin
    Malpas, Charles B.
    Sharmin, Sifat
    Boz, Cavit
    Alroughani, Raed
    Ozakbas, Serkan
    Buzzard, Katherine
    Skibina, Olga
    van der Walt, Anneke
    Butzkueven, Helmut
    Lechner-Scott, Jeannette
    Kuhle, Jens
    Terzi, Murat
    Laureys, Guy
    Van Hijfte, Liesbeth
    John, Nevin
    Grammond, Pierre
    Grand'Maison, Francois
    Soysal, Aysun
    Jensen, Ana Voldsgaard
    Rasmussen, Peter Vestergaard
    Svendsen, Kristina Bacher
    Barzinji, Ismael
    Nielsen, Helle Hvilsted
    Sejbaek, Tobias
    Prakash, Sivagini
    Stilund, Morten Leif Munding
    Weglewski, Arkadiusz
    Issa, Nadia Mubder
    Kant, Matthias
    Sellebjerg, Finn
    Gray, Orla
    Magyari, Melinda
    Kalincik, Tomas
    MSBase Study Grp
    Danish MS Registry Study Grp
    [J]. JAMA NEUROLOGY, 2023, 80 (08) : 789 - 797
  • [2] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [3] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Guo, Rui
    Zhang, Fubo
    Zhang, Chao
    Dong, Shuai
    Zhou, Hongyu
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [4] Rituximab in relapsing-remitting multiple sclerosis
    Schrijver, Hans M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24): : 2645 - 2645
  • [5] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Zhou, Hongyu
    Han, Wenjie
    Zhang, Shihong
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (12):
  • [6] A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis
    Roos, I.
    Hughes, S.
    MacDonnell, G.
    Boz, C.
    Alroughani, R.
    Ozakbas, S.
    Buzzard, K.
    Skibina, O.
    Van der Walt, A.
    Butzkueven, H.
    Lechner-Scott, J.
    Kuhle, J.
    Terzi, M.
    Laureys, G.
    Van Hijfte, L.
    John, N.
    Grammond, P.
    Grand'Maison, F.
    Soysal, A.
    Sellebjerg, F.
    Gray, O.
    Magyari, M.
    Kalincik, T.
    Msbase and Danish Sclerosis Registry Study Grp
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 951 - 953
  • [7] Cost-Utility Analysis Comparing Ocrelizumab vs Rituximab in the Treatment of Relapsing-Remitting Multiple Sclerosis: The Colombian Perspective
    Navarro, Cristian E.
    Betancur, John E.
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2023, 36 : 83 - 91
  • [8] Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis
    Roos, I.
    Sharmin, S.
    Ozakbas, S.
    Horakova, D.
    Havrdova, E. K.
    Boz, C.
    Alroughani, R.
    Patti, F.
    Terzi, M.
    Lechner-Scott, J.
    Izquierdo, G.
    Eichau, S.
    Grammond, P.
    Buzzard, K.
    Skibina, O.
    Prat, A.
    Girard, M.
    Duquette, P.
    Soysal, A.
    Grand'Maison, F.
    Kuhle, J.
    van der Walt, A.
    Butzkueven, H.
    Turkoglu, R.
    Butler, E.
    Laureys, G.
    van Hijfte, L.
    Shaygannejad, V.
    Yamout, B.
    Khoury, S.
    Prevost, J.
    Sidhom, Y.
    Gouider, R.
    Cartechini, E.
    Sanchez-Menoyo, J. L.
    Sa, M. Jose
    Macdonell, R.
    van Pesch, V.
    Ramo-Tello, C.
    McCombe, P.
    Willekens, B.
    Spitaleri, D.
    Ampapa, R.
    Al-Asmi, A.
    Slee, M.
    Besora, S.
    Malpas, C.
    Kalincik, T.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 778 - 780
  • [9] Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
    Mansour A. Alharbi
    Fahad Aldosari
    Ahmed Hasan Althobaiti
    Faris M. Abdullah
    Salman Aljarallah
    Nuha M. Alkhawajah
    Miteb Alanazi
    Yazed AlRuthia
    [J]. BMC Health Services Research, 23
  • [10] Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
    Alharbi, Mansour A.
    Aldosari, Fahad
    Althobaiti, Ahmed Hasan
    Abdullah, Faris M.
    Aljarallah, Salman
    Alkhawajah, Nuha M.
    Alanazi, Miteb
    AlRuthia, Yazed
    [J]. BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
12345